STOCK TITAN

Rallybio (RLYB) SEC Filings, Aug-Sep 2026

RLYB NASDAQ

Rallybio Corporation's SEC filings document material events for a clinical-stage biotechnology issuer developing rare-disease therapies in complement dysregulation and hematology. Its 8-K disclosures cover operating and financial results, clinical or regulatory updates, material agreements, and capital-structure matters tied to its common stock.

The filing record also includes stockholder voting results and governance disclosures, including certificate-of-incorporation amendments, reverse stock split disclosure, Nasdaq Capital Market listing matters, and registered common stock information. Agreement filings describe transactions involving Rallybio IPB, LLC, RE Ventures I, LLC, Recursion and the REV102 ENPP1 program, alongside emerging-growth-company reporting status and other material-event disclosures.

Rhea-AI Summary

Rallybio Corp (RLYB) director Wendy Chung exercised stock options into common shares. On September 16, 2026, she exercised options for 3,562 shares of common stock at an exercise price of $2.38 per share, converting an option position into directly held stock.

The exercised option for 3,562 underlying shares now shows 0 options remaining from that grant, while her direct ownership in Rallybio common stock is reported as 3,562 shares following the transaction. No Rule 10b5-1 trading plan is reported for this activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
insider
-
Rhea-AI Summary

Rallybio Corporation (RLYB) filed an amended Form S-4 to register shares of common stock to be issued in its all‑stock merger with Avenzo Therapeutics, Inc. Based on the assumed exchange ratio of 0.5020, Rallybio expects to issue approximately 193,644,387 shares of common stock and options to purchase 19,136,431 shares, before a proposed reverse stock split. Avenzo stockholders (excluding new investors) are expected to own about 56.6% of the combined company, Rallybio stockholders about 2.8%, and investors in a concurrent Avenzo financing about 40.6%, assuming $215.0 million of financing proceeds.

Rallybio calculates Rallybio Net Cash of about $82.2 million as of August 15, 2026 and plans to distribute substantially all Rallybio Net Cash to pre‑closing stockholders via cash “Parent Distributions” and longer‑dated contingent value rights (CVRs) tied to monetization of its legacy assets and a prior sale to Recursion. Existing Rallybio shares remain outstanding but will be heavily diluted, with closing conditioned on stockholder approval of share issuance, reverse split, name change to Avenzo Therapeutics, Inc., and Nasdaq listing of the combined company under ticker AVZO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
registration
-
Rhea-AI Summary

Rallybio Corp (RLYB) reported a change in the work arrangement of its Chief Financial Officer, Jonathan LieberSeptember 15, 2026base salary of $420,000Avenzo Therapeutics, Inc.May 31, 2026

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.30%
Tags
current report
Rhea-AI Summary

Rallybio Corp (symbol: RLYB) is the issuer of record for a Form S-4/A filing submitted to the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
registration
-
Rhea-AI Summary

Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of Rallybio Corporation common stock. As of June 30, 2026, the group may be deemed to beneficially own 188,422 shares of common stock, representing 3.56% of the outstanding class. All 188,422 shares are reported with shared voting and shared dispositive power, and none with sole power. The filing states that the group holds 5% or less of Rallybio’s common stock, reflecting its status as a significant but non‑controlling shareholder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
ownership
-
Rhea-AI Summary

Cormorant Asset Management, LP and Bihua Chen report that they no longer beneficially own any shares of Rallybio Corp common stock. They state beneficial ownership of 0 shares, representing 0.0% of Rallybio’s common stock, with no sole or shared voting or dispositive power.

The ownership percentages are based on 5,298,137 shares of Rallybio common stock outstanding as of May 8, 2026, as referenced from Rallybio’s Quarterly Report for the period ended March 31, 2026. The filers also indicate that the statement should not be construed as an admission of beneficial ownership for purposes of Section 13.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
ownership
Rhea-AI Summary

Rallybio Corp received an amended Schedule 13G filing from Balyasny Asset Management L.P. and related entities reporting that they are not beneficial owners of Rallybio’s common stock. The reporting group, including BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, reports beneficial ownership of 0 shares, representing approximately 0% of the outstanding common stock, based on 5,298,137 shares outstanding as of May 8, 2026 as reported by Rallybio. The filers state they have no sole or shared voting or dispositive power over any Rallybio shares and confirm ownership of 5 percent or less of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
ownership
-
Rhea-AI Summary

FMR LLC and Abigail P. Johnson report beneficial ownership of Rallybio Corp common stock. As of 06/30/2026, they beneficially owned 794,720 shares of common stock, representing 15.0% of the class identified by CUSIP 75120L209.

FMR LLC has sole voting power over 794,720 shares and no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over 794,720 shares. Within this position, Fidelity Growth Company Commingled Pool held 265,132 shares, equal to 5.0% of Rallybio’s outstanding common stock as of 06/30/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
ownership
-
Rhea-AI Summary

Rallybio Corporation reported a sharp swing to profitability for the quarter ended June 30, 2026, driven by a $50.0 million termination fee from its previously planned merger with Candid Therapeutics. Net income was $43.7 million, or $7.66 per basic share, despite core operations still generating a $5.7 million operating loss in the quarter and $14.4 million for the first half. Cash and cash equivalents rose to $92.8 million, with total assets of $98.1 million and liabilities of $3.6 million.

Strategically, Rallybio agreed to merge with Avenzo Therapeutics and support a $215.0 million concurrent financing for Avenzo. On a fully diluted, pro forma basis, Avenzo equityholders are expected to own about 56.6% of the combined company, Rallybio holders about 2.8% and new financing investors 40.6%, based on assumed valuations of $15.0 million for Rallybio and $300.0 million for Avenzo. Before closing, Rallybio plans to distribute its net cash to existing securityholders and issue contingent value rights that give them pro rata access to future proceeds from divesting Rallybio’s legacy assets, including milestone and royalty streams from the ENPP1 program sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
quarterly report
Rhea-AI Summary

Rallybio Corp received an amended Schedule 13G filing in which Laurion Capital Management LP and its co-managing members, Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, report that they beneficially own 0 shares of Rallybio common stock, representing 0% of the class.

The reporting persons state they have no sole or shared power to vote or dispose of any Rallybio shares, and affirm ownership of 5 percent or less of the outstanding common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
ownership

FAQ

How many Rallybio (RLYB) SEC filings are available on StockTitan?

StockTitan tracks 83 SEC filings for Rallybio (RLYB), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Rallybio (RLYB)?

The most recent SEC filing for Rallybio (RLYB) was filed on November 12, 2026.